Cholecystectomy in a man with hemophilia A and inhibitor on emicizumab prophylaxis: a case report

Página do item simplificado
dc.creatorPaula Cella Giacometto
dc.creatorMarcello Tortelli Bavaresco
dc.creatorJuliana Alvares Teodoro
dc.creatorRicardo Mesquita Camelo
dc.date.accessioned2023-07-18T16:50:29Z
dc.date.accessioned2025-09-08T23:44:31Z
dc.date.available2023-07-18T16:50:29Z
dc.date.issued2021
dc.identifier.doihttps://doi.org/10.1016/j.htct.2022.10.003
dc.identifier.issn2531-1379
dc.identifier.urihttps://hdl.handle.net/1843/56591
dc.languagepor
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofHematology, Transfusion and Cell Therapy
dc.rightsAcesso Aberto
dc.subjectHemofilia
dc.subjectInibidores
dc.subjectColecistectomia
dc.subject.otherHemophilia A
dc.subject.otherInhibitor
dc.subject.otherEmicizumab
dc.subject.otherSurgery
dc.subject.otherCholecystectomy
dc.titleCholecystectomy in a man with hemophilia A and inhibitor on emicizumab prophylaxis: a case report
dc.typeArtigo de periódico
local.citation.epage4
local.citation.spage1
local.citation.volume43
local.description.resumoInherited hemophilia A is a rare bleeding disorder due to absent/reduced activity of the clotting factor VIII (FVIII).1 Therefore, its treatment is based on regular FVIII infusions to prevent (i.e., prophylaxis) or treat (i.e., on demand) bleedings.1 The most impacting complication of this treatment is the development of anti-FVIII antibodies (i.e., inhibitors).1 Inhibitors reduce/abolish the clotting activity of FVIII, rendering the patients with the previous or worse bleeding phenotype, which ultimately leads to increased morbimortality.1 Although bypassing agents (recombinant activated factor VII [rFVIIa] and partially activated prothrombin complex [aPCC]) can be prescribed for both prophylactic and on-demand treatments, the current recommended prophylactic drug in such cases is the humanized bispecific antibody emicizumab.1,2 Emicizumab mimics the clotting effect of FVIII and, since its structure is not similar to the FVIII structure, anti-FVIII inhibitors have no effect on its clotting activity.1,2 There are few reports about the hemostatic effectiveness and safety of this biopharmaceutical on major non-orthopedic surgeries.3, 4, 5 In addition, since the introduction of emicizumab in the armamentarium for hemophilia treatment in Brazil, in 2018, no major surgical procedures have been reported in Brazilian patients on emicizumab prophylaxis. Herein we described a man with severe hemophilia A and high-responding inhibitor under emicizumab prophylaxis who was submitted to open cholecystectomy due to acute-on-chronic calculous cholecystitis. This report was approved by the local Committee on Ethics on Research (May/29/2019). The patient signed the Consent Form before his data was reviewed on the hospital medical files.
local.identifier.orcidhttps://orcid.org/0000-0002-4023-275X
local.identifier.orcidhttps://orcid.org/0000-0003-3685-1555
local.identifier.orcidhttps://orcid.org/0000-0002-0210-0721
local.identifier.orcidhttps://orcid.org/0000-0001-9025-0289
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIAL
local.publisher.initialsUFMG
local.url.externahttps://www.sciencedirect.com/science/article/pii/S2531137922014584?via%3Dihub

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
CholecystectomyinamanwithhemophiliaAand inhibitoronemicizumabprophylaxis Acasereport.pdf
Tamanho:
455.33 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG